A possible explanation is differences in first-pass metabolism among individual ... the rectal suppositories resulted in a mean 16% lower bioavailability compared with the 50-mg oral syrup.

Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a ...